Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Global Vaccines Stories

2014-03-10 16:32:39

RNActive® Vaccines Offer Excellent Conditions for Cost-Effective Worldwide Distribution TUBINGEN, Germany and BRUSSELS, March 10, 2014 /PRNewswire/ -- CureVac, a German clinical stage biopharmaceutical company, today announced that it has won the inaugural European Commission Vaccine Prize. The EU has dedicated the prize of two million Euros in an effort to stimulate innovative solutions for vaccine transportation and storage where cold chain cannot be guaranteed. CureVac's...

2014-02-03 08:28:23

DUBLIN, Ireland, February 3, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/v6rrkv/vaccine_market_by) has announced the addition of the "Concise Analysis of the International Vaccine Market - Global Forecasts To 2022" [http://www.researchandmarkets.com/research/v6rrkv/vaccine_market_by ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) The global vaccine technology market is...

2013-12-26 08:21:16

DUBLIN, December 26, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qv4xvl/animalveterinary) has announced the addition of the "International Animal/Veterinary Vaccines Market 2013-2018" [http://www.researchandmarkets.com/research/qv4xvl/animalveterinary ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Europe accounts for the largest share of the veterinary vaccines market, followed...

2013-10-23 23:25:04

Keynote presentations by vaccine development experts at the 17th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases (NFID), will focus on new technologies and scientific advances to improve global vaccine effectiveness. Additional sessions will focus on topics including future trends in vaccine research and current regulatory and policy challenges. Bethesda, MD (PRWEB) October 23, 2013 Dr. Penny Heaton, Director of Vaccine Development,...

2013-09-06 23:04:12

The global market for vaccine technologies was valued at $33.6 billion in 2012. BCC Research expects the market to reach nearly $43.4 billion by 2017, and register a compound annual growth rate (CAGR) of 5.3%. Wellesley, MA (PRWEB) September 06, 2013 According to a new technical market research report, Global Markets for Vaccine Technologies from BCC Research (http://www.bccresearch.com), the global market for vaccine technologies was valued at $33.6 billion in 2012. BCC Research expects...

2012-07-09 17:45:32

Could pave way for development of enhanced delivery and storage in third world, save billions in cost Researchers funded by the National Institutes of Health have developed a new silk-based stabilizer that, in the laboratory, kept some vaccines and antibiotics stable up to temperatures of 140 degrees Fahrenheit. This provides a new avenue toward eliminating the need to keep some vaccines and antibiotics refrigerated, which could save billions of dollars every year and increase...

2011-10-17 12:33:00

SEATTLE, Oct. 17, 2011 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) has joined the Advanced Immunization Technologies (ADITEC) program, a collaborative initiative dedicated to accelerating the development of the next generation of human vaccines. Launched on October 1st, ADITEC will operate with 30 million euros in funding over the course of 5 years contributed by the European Union, with an additional 11 million euros in funding from collaborating...

2011-09-23 11:42:25

Holds great promise for global public health Innovation in the design of vaccines is rapidly expanding their use, safety, and effectiveness for disease prevention and therapeutic interventions. The enormous potential of OMICS sciences for global health and vaccine design is examined in "Vaccines of the 21st Century and Vaccinomics," a special issue of OMICS: A Journal of Integrative Biology, the peer-reviewed journal published by Mary Ann Liebert, Inc. The issue is available free online....

2011-05-10 12:50:51

Research addresses disparate availability of vaccines in developing countries Combination vaccines for young children are commonly used in industrialized nations because they provide protection for multiple diseases in one single injection. However, combination vaccines are prohibitively expensive for developing countries and may not available until several years later, or when market prices are more affordable. As a result, the choice of vaccines used by developing and industrialized...

2011-01-27 06:00:00

PRINCETON, N.J., Jan. 27, 2011 /PRNewswire/ -- Soligenix, Inc. (Soligenix or the Company) (OTC Bulletin Board: SNGX), a late-stage biopharmaceutical company, today announced that it has entered into a definitive license agreement with the University of Colorado (CU) for novel technology for use in the development of subunit vaccines with long-term stability, including stability at elevated temperatures. The technology is the subject of several United States and foreign patent applications...